COMPARISON
Insulin degludec vs Octreotide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Insulin degludec is authorised or registered in 10 and Octreotide in 10 of the 10 registers read. Insulin degludec: highest phase Phase 4 (after approval). Octreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Insulin degludec | Octreotide | |
|---|---|---|
| Registered trials differs | 255 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Xultophy 100/3.6 openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2013-01-20 ema · 2026-10-03 | 2025-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for insulin-degludec | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | A10AE06 ema · 2026-10-03 | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Insulin degludec | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Diarrhoea | - | - | 46.2% | 31.7% |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Nausea | - | - | 30.8% | 21.2% |
| Fatigue | - | - | 29.8% | 27.7% |
| Rash | - | - | 28.8% | 14.1% |
| Decreased appetite | - | - | 28.5% | 15.2% |
| Hypertension | - | - | 26.5% | 19.4% |
| Dyspnoea | - | - | 25.9% | 9.1% |
| Anaemia | - | - | 24.3% | 9.1% |
Trial register Insulin degludec: 0 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Insulin degludec side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Insulin degludec | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.